The Ministry of Health’s Medicinal Cannabis Agency will open its new process for cultivators and manufacturers of medicinal cannabis. It is hoped that the new rules will provide some relief to medical cannabis patients, even amid the ongoing Covid-19 pandemic.
The new rules includes quality standards for both domestic and imported medicinal cannabis and a licensing framework. It also allows doctors to prescribe the medicines more freely without the need for specialist visits. However, they will only be able to prescribe products that have been approved by the Ministry of Health’s quality standards.
According to Mark Lucas, CEO of licensed New Zealand research company CannaSouth, this is no easy feat:
“There’s a massive amount of work to get in a position where you’re going to be able to produce medicines that make the New Zealand quality standards.”
Medicinal cannabis products must meet Good Manufacturing Practises (GMP) standards. This process requires the completion of extensive documentation, testing, and fees. In addition, the type of products available to patients will be limited. Patients will only be able to access ‘dose form’ medications such as oils, tablets, and creams.
Read more at canex.co.uk